← Back to All Filings

Annexon (ANNX) Director Buys $13K in Company Stock

Low SignificanceOctober 31, 2025 at 4:33:54 PM EDT

Annexon, Inc.

$ANNX4CIK: 0001528115

Subscribe to track ANNX

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Annexon (ANNX) Director Buys $13K in Company Stock

Company: Annexon, Inc. (ANNX) Form: 4 | Filed: 2025-10-31 Significance: Low

Insider: Carson William H. Title: null | Relationship: Director

Transaction: • Type: Purchase • Shares: 4,115 • Price: $3.17 • Value: $13,045 • Owned After: 46,175

Key Insight: A director made a small open-market purchase under a pre-arranged 10b5-1 trading plan. The transaction size is nominal, representing less than 0.01% of the company's market cap.

Market Context: This purchase, while a minor positive signal of insider confidence, is too small to be considered material for a company with a $320 million market capitalization.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: Annexon, Inc. (ANNX)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: A director made a small, pre-planned open-market purchase of common stock, representing a nominal investment relative to the company's market capitalization.
  • Market Impact: The transaction is unlikely to have a material impact on the stock price due to its very small size.

Company Information

FieldValue
CompanyAnnexon, Inc.
Ticker SymbolANNX
CIK0001528115
IndustryPHARMACEUTICAL PREPARATIONS

Insider Information

FieldValue
NameCarson William H.
CIK0001824280
Title/Positionnull
RelationshipDirector

Transaction Details

FieldValue
Form Type4
Transaction Date2025-10-30
Transaction CodeP (Purchase)
Security TypeCommon Stock
Shares Involved4,115
Price Per Share$3.17
Total Value$13,044.55
Shares Owned After46,175
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$13,044.55
% of Market Cap0.004%
Shares Transacted4,115
% of Shares Outstanding0.004%
Post-Transaction Ownership46,175 shares (0.042% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with a market capitalization of $320 million, this $13k transaction is financially insignificant.
  • Ownership Concentration: The purchase slightly increases the director's holding to 46,175 shares, which constitutes a negligible 0.042% of the total shares outstanding. This does not represent a significant concentration of ownership.
  • Transaction Significance: The transaction's value is less than 0.01% of the market cap and the shares involved are less than 0.01% of shares outstanding. Both metrics are far below the thresholds for even moderate significance, categorizing this as a routine, low-impact trade.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: While insider buying is typically a bullish signal, the extremely small size of this transaction relative to the company's market cap and public float makes it highly unlikely to influence investor sentiment or stock price.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The transaction size is too small to impact trading volume.
  • Sentiment Indicator: Neutral. The purchase is a positive action, but its immateriality neutralizes any significant bullish sentiment it might otherwise generate.

Investment Insights

Positive Market Indicators

  • An insider is increasing their direct holdings, which is generally a sign of confidence.

Risk Factors

  • The size of the purchase is nominal, suggesting it may not be a high-conviction buy.

Key Takeaways

  1. A director of Annexon, Inc. purchased 4,115 shares for a total of approximately $13,000.
  2. The transaction was executed under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not necessarily based on immediate, private information.
  3. The trade is of low significance, representing just 0.004% of the company's market cap and shares outstanding, and is unlikely to be a market-moving event.

Additional Context

Special Circumstances

  • The filing's footnotes confirm the purchase was made pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2025. This reduces the signal value of the trade as it was planned well in advance.
Topics:#SECFiling#InsiderTrading#ANNX#Annexon#Form4#InsiderBuy#StockMarket#Investing#Biotech#MarketAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.